Evidence map›Paper›PMID 33676511›Full record

ArticleBMC medical genomics2021

Analysis of long-term observations of the large group of Russian patients with Hunter syndrome (mucopolysaccharidosis type II).

Alla Nikolaevna Semyachkina, Elena Yurievna Voskoboeva, Ekaterina Alexandrovna Nikolaeva, Ekaterina Yurievna Zakharova

Open access · goldAbstract read
In one paragraph

Article in BMC medical genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Differences in MPS I and MPS II Disease Manifestations.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Alla Nikolaevna Semyachkina *Department of Clinical Genetics, Research and Clinical Institute of Pediatrics Named After Yuri Veltischev of the Pirogov Russian National Research Medical University of the Russian Ministry of Health, 2 Taldomskaya St., Moscow, 125412, Russia. gokhramenko@pedklin.ru.ORCID 0000-0002-4026-3791
Elena Yurievna Voskoboeva *Research Centre for Medical Genetics RAN, 1 Moskvorechie St., Moscow, 115522, Russia.
Ekaterina Alexandrovna NikolaevaDepartment of Clinical Genetics, Research and Clinical Institute of Pediatrics Named After Yuri Veltischev of the Pirogov Russian National Research Medical University of the Russian Ministry of Health, 2 Taldomskaya St., Moscow, 125412, Russia.
Ekaterina Yurievna ZakharovaResearch Centre for Medical Genetics RAN, 1 Moskvorechie St., Moscow, 115522, Russia.
Pirogov Russian National Research Medical University · RUResearch Centre for Medical Genetics · RU

Funding

Russian Ministry of Health АААА-А18-118051790107-2
6 · The paper itself

Abstract

backgroundThis article presents the results of long-term observations and comparative analysis of genotype-phenotype features in a large group of patients (227 males and one female) with a severe, intermediate and mild form of Hunter syndrome, evaluating the quality and span of their lives, as well as their ability to social adaptation.

methodsWe used electrophoresis of glycosaminoglycans of urine, determination of the activity of lysosomal enzymes in plasma, in dried blood spots according to the generally accepted method and DNA analysis.

resultsThe clinical symptomatology of 228 patients with Hunter syndrome was characterized by growth retardation, lesions of the bronchopulmonary, cardiovascular, nervous systems, etc. Thirty-five patients had an attenuated form of the disease. DNA was available from all patients. 19 patients from 10 families had a mild form of the disease. 42 patients from 41 families had an intermediate form of the disease. All other patients had a severe form of the disease. We provide brief clinical examples of some patients with a mild form of Hunter syndrome. Currently, 113 patients with Hunter syndrome receive enzyme replacement therapy (idursulfase or idursulfase beta).

conclusionThe long-term study of the large number of patients with Hunter syndrome helped identify disease-associated variants leading to severe and mild forms of the disease. The treatment effect and successful social adaptation of patients with a mild form of Hunter syndrome were revealed.

Indexed as

Mucopolysaccharidosis IIAdolescentAdultChildChild, PreschoolEnzyme Replacement TherapyFemaleGlycosaminoglycansHumansIduronate SulfataseInfantMalePhenotypeRussiaYoung AdultGlycosaminoglycansIduronate SulfataseClinical and genetic analysisHunter syndromeMucopolysaccharidosisSocial adaptation

Identifiers

PMID33676511
PMCPMC7937197
OpenAlexW3134991594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.